DiaMedica Therapeutics

OverviewSuggest Edit

DiaMedica Therapeutics is a biopharmaceutical company which engages in the development of treatments for neurological and kidney diseases. The Company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications. It is also developing DM199 for the treatment vascular dementia.

TypePublic
Founded2000
HQMinneapolis, US
Websitediamedica.com

Latest Updates

Employees (est.) (Jun 2019)26(+189%)
Revenue (FY, 2018)$500 K
Share Price (Mar 2020)$2.8 (+8%)

Key People/Management at DiaMedica Therapeutics

Richard Pilnik

Richard Pilnik

Chairman of the Board
Michael Giuffre

Michael Giuffre

Director
Sydney Gilman

Sydney Gilman

VIce President, Regulatory Affairs
Scott Kellen

Scott Kellen

Chief Financial Officer
Rick Pauls

Rick Pauls

President & CEO, Director
Zhenyu Xiao

Zhenyu Xiao

Director
Show more

DiaMedica Therapeutics Office Locations

DiaMedica Therapeutics has an office in Minneapolis
Minneapolis, US (HQ)
2 Carlson Parkway, Suite 260
Show all (1)

DiaMedica Therapeutics Financials and Metrics

DiaMedica Therapeutics Revenue

DiaMedica Therapeutics's revenue was reported to be $500 k in FY, 2018
USD

Net income (FY, 2019)

(10.6m)

EBIT (FY, 2019)

(11.6m)

Market capitalization (26-Mar-2020)

33.8m

Closing stock price (26-Mar-2020)

2.8

Cash (31-Dec-2019)

3.9m

EV

30.1m
DiaMedica Therapeutics's current market capitalization is $33.8 m.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Revenue

500.0k

General and administrative expense

598.0k1.3m2.7m3.7m

R&D expense

1.7m3.2m4.5m7.9m

Operating expense total

2.3m4.5m7.3m11.6m
Quarterly
USDQ3, 2017Q3, 2018Q1, 2019Q2, 2019Q3, 2019

General and administrative expense

415.0k777.0k814.0k867.0k1.0m

R&D expense

411.0k1.2m2.6m1.9m1.6m

Operating expense total

826.0k2.0m3.4m2.7m2.7m

EBIT

(826.0k)(1.5m)(3.4m)(2.7m)(2.7m)
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Cash

1.7m1.4m16.8m3.9m

Accounts Receivable

53.0k80.0k780.0k823.0k

Prepaid Expenses

67.0k61.0k369.0k47.0k

Current Assets

1.9m1.5m18.0m8.8m
Quarterly
USDQ3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

3.9m2.8m3.0m4.7m

Accounts Receivable

1.0m929.0k1.1m664.0k

Prepaid Expenses

160.0k298.0k198.0k89.0k

Current Assets

5.1m14.9m12.3m10.8m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(2.2m)(4.3m)(5.7m)(10.6m)

Depreciation and Amortization

2.0k4.0k15.0k21.0k

Accounts Payable

(510.0k)248.0k372.0k(301.0k)

Cash From Operating Activities

(3.0m)(3.9m)(5.7m)(9.1m)
Quarterly
USDQ3, 2017Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Net Income

(3.5m)(3.8m)(3.3m)(5.7m)(8.2m)

Depreciation and Amortization

2.0k10.0k6.0k11.0k16.0k

Accounts Payable

54.0k434.0k201.0k(221.0k)(171.0k)

Cash From Operating Activities

(2.9m)(3.8m)(3.1m)(6.0m)(7.2m)
USDY, 2019

EV/EBIT

-2.6 x

EV/CFO

-3.3 x

Financial Leverage

1.2 x
Show all financial metrics

DiaMedica Therapeutics Acquisitions / Subsidiaries

Company NameDateDeal Size
DiaMedica Australia Pty Ltd
DiaMedica USA

DiaMedica Therapeutics Online and Social Media Presence

Embed Graph

DiaMedica Therapeutics News and Updates

DiaMedica Therapeutics to Report Second Quarter 2019 Financials and Provide a Business Update August 13, 2019

MINNEAPOLIS, Aug. 08, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its second quarter 2019 financial results will be released after the markets close on Tuesday, August 13th. DiaMedica will host a live conference call on Wednesday, August 14th at 7:00am …

DiaMedica Therapeutics Announces Interim Results from Phase 1b Trial of DM199 in Chronic Kidney Disease Participants

MINNEAPOLIS, June 19, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, today announced interim results of the Phase 1b study from 28 evaluable participants with moderate and severe chronic kidney disease (CKD). DM199 (recombinant KLK1) wa…

DiaMedica Therapeutics to Present at the 16th Annual Craig-Hallum Institutional Investor Conference on May 29, 2019

MINNEAPOLIS, May 22, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that it will be participating in the 16th Annual Craig-Hallum Institutional Investor Conference on Wednesday, May 29, 2019, at the Depot Renaissance Minneapolis Hotel in Minneapolis, MN.  Manag…

DiaMedica Therapeutics Announces Formation of Scientific Advisory Board for Kidney Disease

MINNEAPOLIS, May 21, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for kidney diseases and neurological disorders, today announced the formation of a Scientific Advisory Board (“SAB”) for chron…

DiaMedica Therapeutics Announces First Quarter 2019 Financial Results and Provides Business Update

MINNEAPOLIS, May 13, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for kidney diseases and neurological disorders, today provided a business update and reported its financial results for the t…

DiaMedica Therapeutics to Report First Quarter 2019 Financials and Provide an Update on Development Programs on May 14, 2019

MINNEAPOLIS, May 06, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its first quarter 2019 financial results will be released after market close on Monday, May 13th.  DiaMedica’s management will host a live conference call on Tuesday, May 14th at 7:00am Ce…
Show more

DiaMedica Therapeutics Blogs

DiaMedica Therapeutics Announces Clearance to Initiate Phase II Clinical Trial of DM199 for Chronic Kidney Disease

MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company’s Phase II clinical trial protocol for the treatment of Chronic Kidney Disease (CKD). The Phase II trial is designed to assess the s…

DiaMedica Therapeutics Frequently Asked Questions

  • When was DiaMedica Therapeutics founded?

    DiaMedica Therapeutics was founded in 2000.

  • Who are DiaMedica Therapeutics key executives?

    DiaMedica Therapeutics's key executives are Richard Pilnik, Michael Giuffre and Sydney Gilman.

  • How many employees does DiaMedica Therapeutics have?

    DiaMedica Therapeutics has 26 employees.

  • Who are DiaMedica Therapeutics competitors?

    Competitors of DiaMedica Therapeutics include NeuroPace, Ampio Pharmaceuticals and Inovio Pharmaceuticals.

  • Where is DiaMedica Therapeutics headquarters?

    DiaMedica Therapeutics headquarters is located at 2 Carlson Parkway, Suite 260, Minneapolis.

  • Where are DiaMedica Therapeutics offices?

    DiaMedica Therapeutics has an office in Minneapolis.

  • How many offices does DiaMedica Therapeutics have?

    DiaMedica Therapeutics has 1 office.